ACCD Accolade Inc: Net earnings per share (EPS TTM)

Public company logo of Accolade, Inc. (ACCD)

Accolade has entered a phase of margin expansion and profitability, leveraging cloud services and AI to handle claims without increasing headcount. Net income per share over 12 months helps assess business sustainability, with the value of -2.25 reflecting the most recent figure. Long-term contracts with corporations for benefits management guarantee the company a stable stream of subscription payments.

ACCD Accolade Net earnings per one share for the last twelve months (07/04/2022 - 04/19/2025)

Summary analytical data breakdowns for Accolade Inc (ACCD)

- stock price and consensus target price:
Stock Price Accolade Health|ACCD - Consensus Target
- company stock capitalization data:
Market Capitalization Accolade, Inc.|ACCD - Real Price to Acquire Entire Company
- business book valuation details:
Net Assets per Single Share Accolade|ACCD - Total Stockholders' Equity|Market Value to Book Value Ratio accolade.com|ACCD - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Capital Accolade|ACCD - Long-Term Debt to Capital|Short-Term Debt to Capital Accolade Health|ACCD - Company Aggregate Debt|Debts to Book Capitalization Accolade, Inc.|ACCD - Long-Term Debt|Company Short-Term Debts Accolade|Quick Ratio accolade.com
- earnings and multiples data:
ACCD - Net Income|Projected Future Earnings Accolade|ACCD - Price to Earnings Ratio|Forward P/E Multiple Accolade Health|ACCD - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Accolade, Inc.|ACCD - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Accolade|ACCD - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months accolade.com|ACCD - Earnings per share growth in current year|Earnings growth forecast for next year Accolade
Fundamental valuation:accolade.com (ACCD)
Manufactured products of Accolade Inc

Long-term investing requires rigorous asset filtering through the lens of earnings sustainability. Accolade relies on strong human capital, where its mission to simplify healthcare attracts high-value IT specialists. This snapshot of earnings per share over the last 12 months demonstrates net income distributed across the total share issuance. This metric allows for an assessment of the real return on a single equity stake without the influence of one-off factors. The stability of this indicator confirms the operational efficiency and fundamental strength of Accolade.

Main competitors

Hims & Hers Health - Net earnings per share (EPS TTM)|hingehealth.com (HNGE) - Net earnings per share for the last 12 months|TDOC: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Talkspace Inc|Earnings per share for the last twelve months LifeMD Inc.|Net earnings per one share for the last twelve months Amwell Inc. AMWL|Earnings per share for the last twelve months Mangoceuticals, Inc. (MGRX)|Earnings per share for the last twelve months DRIO (mydario.com)|Net earnings per share (EPS TTM) VSEE (VSee Health)|Net earnings per share (EPS TTM) Mobile-health Network Solutions Inc MNDR|Biotricity, Inc - Net earnings per share (EPS TTM)|LYT (Lytus) - Earnings per share for the last 12 months|OTRK: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SHL Telemedicine (SHLT)|THRN (Thorne HealthTech, Inc.) - Net earnings per share (EPS TTM)